Zobrazeno 1 - 10
of 23
pro vyhledávání: '"K Imadalou"'
Autor:
Agnès Suc, C. Regnier, P Izard, Delsol G, J Guitard, M. Delsol-Tahou, Rubie H, P. Brousset, Claeyssens S, Alain Robert, K Imadalou
Publikováno v:
Archives de Pédiatrie. 3:977-983
Resume La valeur pronostique de la recherche clinique et histologique d'une infiltration leucemique testiculaire residuelle a l'arret du traitement est encore discutee. L'introduction des techniques immunohistochimiques modernes pourrait ameliorer le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e384ea7923e43c6f0895f13ad1df0bf
https://doi.org/10.1016/0929-693x(96)81718-0
https://doi.org/10.1016/0929-693x(96)81718-0
Autor:
G. Blanchot, Laura Adamoli, Giuseppina Sanna, Chiara Catania, Franco Nolè, K. Imadalou, A. Goldhirsch, B. Longerey, Elisabetta Munzone
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 17(2)
Purpose: A phase I study was performed to determine the maximal tolerated dose, recommended doses (RDs), safety and efficacy of oral vinorelbine when combined with capecitabine in an all-oral chemotherapy regimen in patients with metastatic breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78dba61473522576b2439fbf75d9e476
https://pubmed.ncbi.nlm.nih.gov/16303864
https://pubmed.ncbi.nlm.nih.gov/16303864
Autor:
K, Imadalou, E, Cvitkovic
Publikováno v:
Bulletin du cancer. 86(2)
The randomised trial is the best context for the assessment of any new molecule in oncology. The authors emphasize the methodological aspects of randomised trials and suggest strategies to be adopted in phase III trials, based on the newly orthodox c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::417f99e39a348d051286205c181523f6
https://pubmed.ncbi.nlm.nih.gov/10066944
https://pubmed.ncbi.nlm.nih.gov/10066944
Autor:
C. Pondarré, A. Gouyette, K. Imadalou, E. Lucchi, Jackie Morizet, F Pein, A. Santos, Gilles Vassal, C. Cappelli, I Boland, C. Thomas
Publikováno v:
Biochimie. 80(3)
Although the prognosis of childhood cancers has dramatically improved over the last three decades, new active drugs are needed. Camptothecins represent a very attractive new class of anticancer drugs to develop in paediatric oncology. The preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::096b74c0a25e62cc4a7381ddf13645ea
https://pubmed.ncbi.nlm.nih.gov/9615866
https://pubmed.ncbi.nlm.nih.gov/9615866
Autor:
K, Imadalou, H, Rubie, P, Brousset, J, Guitard, A, Suc, M, Delsol-Tahou, S, Claeyssens, P, Izard, A, Robert, G, Delsol, C, Regnier
Publikováno v:
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 3(10)
The prognostic value of clinical and histological detection of testicular leukemia after completion of therapy is still debated. Immunohistochemical study could improve the results of this detection.Between 1982 and 1992, 70 consecutive boys with acu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b867c5c2669d8ef7bc9551d4cec03342
https://pubmed.ncbi.nlm.nih.gov/8952791
https://pubmed.ncbi.nlm.nih.gov/8952791
Publikováno v:
Cancer Research. 69:3138
Abstract #3138 Pertuzumab (P), a humanized monoclonal antibody, is a first-in-class HER heterodimer inhibitor that binds to the HER2 dimerization domain, inhibiting the interaction of HER2 with other HER family members. Xenograft studies demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::300a2e17fad224e03d8f8f62932bd64b
https://doi.org/10.1158/0008-5472.sabcs-3138
https://doi.org/10.1158/0008-5472.sabcs-3138
Autor:
Giuseppina Sanna, Aron Goldhirsch, Diana Crivellari, G. Pinotti, C. Catania, A. Bodini, P. Foa, F. Nolè, K. Imadalou, R. Mattioli
Publikováno v:
European Journal of Cancer Supplements. 5:218
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f4461c854e36109ca7d8fe8c0accfcc
https://doi.org/10.1016/s1359-6349(07)70876-5
https://doi.org/10.1016/s1359-6349(07)70876-5
Autor:
Catania, D. Leroux, Giuseppina Sanna, P. Foa, G. Pinotti, A. Goldhirsch, K. Imadalou, F. Nolè, R. Mattioli, Diana Crivellari
Publikováno v:
European Journal of Cancer Supplements. 4:167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b6c9a78c2cb0c9f3b41056a716a11bd
https://doi.org/10.1016/s1359-6349(06)80428-3
https://doi.org/10.1016/s1359-6349(06)80428-3
Autor:
G. Zorza, K. Imadalou, A. Goldhirsch, Laura Adamoli, Giuseppina Sanna, Franco Nolè, Chiara Catania, A. Bodini
Publikováno v:
Journal of Clinical Oncology. 23:666-666
666 Background: The study investigated oral vinorelbine (NBV oral) and Capecitabine (CAP) combination, which offers the convenience of an all-oral regimen. Methods: to determine maximal tolerated d...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e75c7f8ac22fd8ad0121a695b6f5278
https://doi.org/10.1200/jco.2005.23.16_suppl.666
https://doi.org/10.1200/jco.2005.23.16_suppl.666
Autor:
Roland Bugat, Jaafar Bennouna, Hervé Perrier, F. Husseini, J.-Y. Douillard, Jean-Pierre Delord, K. Imadalou, Bernard Paillot, Pascal Artru, Frank Priou
Publikováno v:
Journal of Clinical Oncology. 22:3545-3545
3545 Background: UFT/LV has demonstrated comparable efficacy to 5-FU/LV iv regimens with clinical safety advantages [Douillard, Carmichael JCO 2002]. 5-FU based regimens containing irinotecan or oxaliplatin are the standard of care for pts with first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24975c0de9027aa6919fc9fe6ae34714
https://doi.org/10.1200/jco.2004.22.90140.3545
https://doi.org/10.1200/jco.2004.22.90140.3545